Peripheral artery disease (PAD) and heart failure (HF) share many risk factors; however, the prevalence and characteristics of HF in patients with PAD have not been fully examined. We investigated 120 consecutive patients with PAD, defined by an anklebrachial index 0.9. In all, 36 (30%) patients had brain natriuretic peptide (BNP) levels !100 pg/mL (high BNP group), and 84 (70%) patients had BNP levels <100 pg/mL (low BNP group). Univariate analysis showed that high BNP was associated with age, estimated glomerular filtration rate, hypertension, and transmitral E-wave/early diastolic mitral annular velocity (E/e 0 ) ratio. Multivariate logistic regression analysis established that a high BNP was strongly and independently associated with the highest quartile of E/e 0 , highlighting these patients' diastolic dysfunction. The prevalence of high BNP levels in patients with PAD suggests that routine BNP measurements might be useful to detect HF.
Introduction
Levels of natriuretic peptides are elevated in patients with left ventricular (LV) dysfunction or LV hypertrophy (LVH). Furthermore, high plasma levels of brain natriuretic peptide (BNP) or the amino terminal fragment of BNP (NT-pro-BNP) predict mortality in patients with or without known cardiovascular disease. 1 It has been postulated that in response to increased intravascular volume there is increased ventricular wall stretch, resulting in the release of BNP into the circulation.
Peripheral artery disease (PAD) is associated with a 2-fold increase in the prevalence of heart failure (HF), defined as a total clinical score. 2 Given that HF and PAD share many risk factors, including increased age, diabetes, smoking, atherosclerosis, and poor renal function, it is not surprising that the prevalence of HF in patients with PAD ranges from 5.8% to 13.9%. 2 The association between PAD and cardiovascular disease and the increasing prevalence of HF suggest that HF is an important clinical concern in these patients.
Patients with PAD have been reported to have higher circulating levels of NT-pro-BNP than controls. Svensson et al found that NT-pro-BNP was significantly elevated in 103 males with PAD compared to controls. 3 In the multivariate analysis of the combined population, the increased prevalence of LVH, ischemic heart disease, and hypertension (HT) explained the high NT-pro-BNP levels in that patient group. However, echocardiography was not performed in that study, and the separate contributions of LVH and LV dysfunction to variations in NT-pro-BNP levels were not distinguished. Montagnana et al measured NT-pro-BNP levels in 35 patients with PAD and 20 controls and found that the values were substantially higher in the patients than in the controls (62.6 vs 7.4 pmol/L, P <.0001). 4 Jouni et al also reported higher levels of NT-pro-BNP in patients with PAD than in age-and sexmatched controls. 5 Despite these reports, the characteristics of HF in patients with PAD have not been fully examined. In this study, we measured plasma BNP levels and evaluated LV function by echocardiography in patients with PAD.
Materials and Methods
The study population was retrospectively recruited from consecutive patients who were admitted to Shinshu University Hospital, Nagano, Japan and had an ankle-brachial pressure index (ABI) of 0.9. Patients with an acute coronary syndrome, a history of HF, or chronic renal failure were excluded. A total of 120 patients with PAD were finally included.
Diabetes mellitus was defined as elevation of fasting glucose levels (!126 mg/dL) or pharmacological treatment. Hypertension was defined as systolic blood pressure (BP) !140 mm Hg and/or diastolic BP !90 mm Hg, or the use of antihypertensive treatment. Hyperlipidemia was defined as total cholesterol level of !220 mg/dL or the use of lipid-lowering agents. Estimated glomerular filtration rate (eGFR) was calculated using the following equation: eGFR (mL/min per 1.73 m 2 ) ¼ 194Cr À1094 Â Age À0.287 (Â 0.739 for female patients). 6 The plasma BNP concentration was obtained using a specific immunoradiometric assay for human BNP (Shionoria kit, Shionogi Co, Ltd, Japan). 7 This assay system uses 2 monoclonal antibodies against human BNP; one recognizes a carboxy terminal sequence and the other the ring structure of human BNP. The system measures human BNP by sandwiching it between the 2 antibodies without extraction of plasma. The minimal detectable quantity of human BNP is 2 pg/mL and the normal upper value is 18.4 pg/mL.
The ABI was measured using the FORM ABI/PWV (Omron Colin Co, Japan). The FORM ABI/PWV is a device with 4 cuffs that can measure BP simultaneously in both arms and both legs and automatically calculates the ABI.
Ultrasound examinations were performed using commercially available echocardiographic machines. The following measurements of global LV diastolic function were determined: peak velocities of E and A waves and their ratio E/A, and pulmonary venous flow (PVF) velocities. Mean early diastolic mitral annular velocity (e 0 ) was estimated by the septal value. The LV filling pressure was estimated by calculating the transmitral E-wave/early diastolic mitral annular velocity (E/e 0 ) ratio. The echocardiographic parameters could not be derived in some patients.
Statistical Analysis
Categorical variables were expressed as absolute frequency and relative frequency (percentage) and compared using the chi-square test. Continuous variables were expressed as mean + standard deviation and were compared using the Mann-Whitney test. The magnitude of the association between clinical variables and BNP was quantified in terms of the odds ratio (OR) and the 95% confidence interval (CI) using univariate logistic regression analysis. Multiple logistic regression analyses were then performed with adjustment for significant parameters. A 2-sided P <.05 was considered significant. All statistical analyses were performed using IBM SPSS Statistics 18 software (IBM Co, USA).
Results
The characteristics of the total population and subgroups are shown in Table 1 . The mean BNP level of the 120 patients with PAD was 133.6 + 225.1 pg/mL. In all, 36 (30%) patients had BNP levels !100 pg/mL (high BNP group) and 84 (70%) patients had BNP levels <100 pg/mL (low BNP group). Patients in the high BNP group were older, had higher prevalence of atrial fibrillation and HT, higher diastolic BP and creatinine levels, and lower eGFR and high-density lipoprotein (HDL) than patients in the low BNP group. On ultrasound examination, LVEF did not differ between the high and low BNP groups, but the values of E and E/e 0 , PVF-peak diastolic velocity (PVF-D), and left atrial diameter (LAD) were significantly higher, and the ratio of PVF-peak systolic velocity (PVF-S) to PVF-D (PVF-S/D) was significantly lower in the high BNP group (Table 2) . Table 3 shows the correlation of BNP levels with various parameters; significant positive correlations were observed with age and E/e 0 , and significant negative correlations were observed with resting heart rate, diastolic BP, eGFR, HDL cholesterol, low-density lipoprotein cholesterol, and PVF-S/D. Univariate analyses showed that high BNP (!100 pg/mL) was associated with age, eGFR, and the quartile of E/e 0 ( Table 4 ). Multivariate logistic regression analyses with adjustments for age, sex, eGFR and quartile of LVEF, and E/e 0 established that the highest quartile of E/e 0 was independently associated with high BNP levels (OR 2.31, 95% CI 1.37-3.89, P ¼ .002; Table 4 ). A BNP level !100 pg/mL was independently predicted by the highest quartile of E/e 0 in patients with PAD.
Discussion
This study demonstrated a high prevalence of high BNP levels in patients with PAD. This is not surprising considering the high prevalence of concomitant ischemic heart disease, renal dysfunction, and HT in these patients, but the relation to these Abbreviations: PVF-S, pulmonary venous flow-peak systolic velocity; PVF-D, PVF-peak diastolic velocity; IVSd, interventricular septal thickness at end diastole; LVPWd, left ventricular posterior wall thickness at end diastole; LVEF, left ventricular ejection fraction; LAD, left atrial diameter; BNP, brain natriuretic peptide; E/A, peak velocities of E and A waves and their ratio; E/e 0 , transmitral E-wave/early diastolic mitral annular velocity. factors did not remain significant in a multiple regression analysis. The very strong (OR ¼ 2.31) independent association between high BNP levels and the E/e 0 ratio, which reflects LV filling pressures, highlights the presence of diastolic dysfunction in these patients.
Morrison et al reported that BNP accurately detected HF (sensitivity 86%, specificity 98%) at a cutoff of 94 pg/mL. 8 In the present study, 30% of the patients with PAD had plasma BNP levels !100 pg/mL and were diagnosed as having HF. Greater hemodynamic and myocardial stress as a result of increased ventricular stiffness is a plausible mechanism underlying high BNP levels in patients with PAD, although BNP secretion by ischemic skeletal muscles has recently been reported and may also be a contributory factor. 9 The NT-pro-BNP levels were found to be predictive of mortality in patients with PAD in 2 previous studies. 10, 11 However, the utility of NT-pro-BNP or BNP as a predictor of HF and adverse outcomes in patients with PAD needs further investigation. In this study, the prevalence of HF was high in patients with PAD, and BNP may be useful as an inexpensive screening tool to risk-stratify the patients with PAD. The increased levels of BNP found in these patients could be considered a sign of early myocardial dysfunction, warranting further heart examination and strict follow-up.
Management of PAD is mainly based on reduction of systemic cardiovascular risk, such as smoking cessation, exercise, treatment of HT and diabetes, and the use of antiplatelet agents and statins. 12, 13 Walking and physical training have been shown to improve claudication distance in patients with PAD. Cilostazol, a phosphodiesterase-3 inhibitor approved for use in symptomatic PAD, 12, 13 is contraindicated in HF (a black-box warning). Therefore, when we use this type of medicine, we should take into account that the prevalence of HF is high in patients with PAD.
To our knowledge, this study is the first to demonstrate a high prevalence of diastolic dysfunction in patients with PAD. However, our study has several potent limitations. One limitation is that our patient population was a selected subgroup of the overall PAD population in a single center. Another limitation is that control participants who did not have a history of PAD and with an ABI >0.9 were not included in the study. In addition, echocardiographic parameters could not be obtained in some cases. Besides, the number of patients in this study was small, and further studies are needed to characterize HF in PAD.
This study demonstrated a high prevalence of high BNP levels with diastolic dysfunction in patients with PAD. This suggests that routine BNP measurements may be useful for the early detection of HF in this population.
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